ozanimod

BMS' Recently Approved MS Drug Shows Promise in Ulcerative Colitis Study
BMS' Recently Approved MS Drug Shows Promise in Ulcerative Colitis Study
BioSpace
Bristol-Myers Squibb
Zeposia
ozanimod
ulcerative colitis
Flag link:
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Just in time to assure a decision before CVR deadline, Bristol Myers Squibb files NDA for Celgene/bluebird CAR-T
Endpoints
Bristol-Meyers Squibb
CAR-T
Celgene
ide-cel
Bluebird Bio
liso-cel
ozanimod
Flag link:
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
Xconomy
Bristol-Meyers Squibb
Celgene
M&A
ozanimod
MS
mutliple sclerosis
drug launches
FDA
COVID-19
Zeposia
Flag link:
Go or no go? Covid-19 upstages US regulatory decisions
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
Flag link:
Janssen files MS pill, ahead of FDA decision on BMS’ rival
Janssen files MS pill, ahead of FDA decision on BMS’ rival
Pharmaforum
Janssen
JNJ
multiple sclerosis
MS
FDA
ponesimod
Bristol-Myers Squibb
ozanimod
Flag link:
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
Flag link:
A Big Month Ahead for the FDA and Bristol-Myers Squibb
A Big Month Ahead for the FDA and Bristol-Myers Squibb
Motley Fool
Bristol-Myers Squibb
Celgene
FDA
ozanimod
Opdivo
Reblozyl
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Bristol-Myers confident of approvals linked to higher Celgene investor payout: Bristol executive
Reuters
Bristol-Myers Squibb
Celgene
M&A
liso-cel
ozanimod
bb2121
FDA
Flag link:
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
ozanimod
liso-cel
bb2121
Flag link:
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Fierce Pharma
Celgene
multiple sclerosis
MS
ozanimod
drug marketing
Flag link:
3 Drugs Under FDA Review With Blockbuster Potential
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Flag link:
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Endpoints
Celgene
FDA
EMA
ozanimod
multiple sclerosis
Flag link:
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Celgene
ozanimod
MS
multiple sclerosis
Flag link:
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Flag link:
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
Flag link:
3 Potential New Drugs Held Up by the Shutdown
3 Potential New Drugs Held Up by the Shutdown
Motley Fool
FDA
government shutdown
Aimmune Therapeutics
AR 101
Celgene
fedratinib
Bristol-Myers Squibb
ozanimod
Flag link:
The 20 Hottest Pipeline Drugs to Watch in 2019
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Celgene to launch five new products through to 2020
Celgene to launch five new products through to 2020
PM Live
Celgene
Revlimid
FDA
fedratinib
ozanimod
luspatercept
bb2121
liso-cel
Flag link:

Pages